Breaking
new ground
in Genetic Medicine
Gene therapy for diseases regardless of their prevalence
OUR STORY
LEXEO Therapeutics was founded in 2018, based on a well-established gene therapy research legacy at Weill Cornell Medicine’s Department of Genetic Medicine by a team of pioneering scientists, clinicians, and business leaders with deep expertise in gene therapy.
Our Science
The possibilities
are endless
LEXEO’s gene therapy product candidates target the underlying causes of both rare monogenic diseases and diseases affecting more prevalent patient populations. We utilize adeno-associated viruses (AAV) that have been engineered to transfer therapeutic genes to patients. LEXEO’s investigational therapies have the potential to address genetically defined cardiovascular and central nervous system (CNS) diseases that have eluded today’s existing drug delivery platforms.
Gene therapy for diseases regardless of their prevalence
